

Reliability of serum procalcitonin concentration for the diagnosis of sepsis in elderly patient with chronic kidney disease

A. Lo Buglio*, F. Bellanti*, M. Talia, A.D. Romano, G. Serviddio, G. Vendemiale

Institute of Internal Medicine, Department of Medical and Surgical Sciences, University of Foggia, Italy

* These Authors equally contributed to this work.

Background and aims. Sepsis is complicated by high mortality in hospitalized patients. Procalcitonin (PCT) is a validated tool in the diagnosis of sepsis in both adults and aged patients. Several studies demonstrated the reliability of PCT in adults with chronic kidney disease (CKD), but this has not been studied in the geriatric population. Thus, we aimed at evaluating the reliability of PCT in a group of elderly patients with CKD.

Methods. 382 subjects (mean age, 78.9 years) were consecutively enrolled and stratified in two groups at the time of the admission based on the absence or presence of CKD, defined as estimated Glomerular Filtration Rate (e-GFR) less than 60 ml/min/1.73 m². These two groups were further divided according to the presence (SEPSIS/NO CKD, n = 41; SEPSIS/CKD, n = 45) or absence of sepsis (NO SEPSIS/NO CKD, n = 147; NO SEPSIS/CKD, n = 149), and the serum PCT was analyzed.

Results. PCT was highly sensitive and specific in patients presenting with sepsis and no CKD. The mean serum PCT concentration in the group SEPSIS/CKD was significantly higher than in NO SEPSIS/CKD (21.00 [5.83 to 97.00] ng/ml vs 0.90 [0.24 to 1.32] ng/ml, p < 0.001). However, the PCT threshold value was 1.7 ng/ml (sensitivity 91.1%, specificity 88.6%) as compared with the currently used threshold value of 0.5 ng/ml (sensitivity 93.3%, specificity 30.2% in our population study).

Conclusions. Our study confirms the diagnostic reliability of PCT for the diagnosis of sepsis in elderly patients with CKD. Nevertheless, we suggest to apply a cut-off of 1.7 ng/ml in this population.

Key words: Circulating procalcitonin, Chronic kidney disease, Sepsis

INTRODUCTION

Sepsis is defined as a systemic inflammatory response secondary to an acute infection¹. The incidence of sepsis and sepsis-related mortality has increased over the past 30 years, particularly in elderly people and it is now the 10th leading cause of death in the United States^{2,3}. Approximately 750,000 people per year are affected by severe sepsis, and more than 50% of the affected population is over 65 years old⁴. Since the aging population is increasing worldwide, the incidence of sepsis is expected to raise in the future. In aged patients, the

atypical symptoms and presentation can make sepsis difficult to diagnose clinically, leading to a delay in both diagnosis and initiation of therapy, thus resulting in increased mortality⁵⁻⁸. Assessment of procalcitonin (PCT) level in serum may be helpful in rapid diagnosis of sepsis⁹. PCT is the precursor of calcitonin produced by thyroid C cells circulating in the blood at very low concentrations (< 0.05 ng/ml) in healthy subjects; during bacterial infections, PCT production increases rapidly in all parenchyma^{10,11}. PCT production is stimulated by both cytokines and bacterial endotoxin or lipopolysaccharide¹². The utility of PCR is not only due to the

Received: May 24, 2016 - Accepted: June 27, 2016

Correspondence: Francesco Bellanti, Department of Medical and Surgical Sciences, University of Foggia, viale Pinto, c/o Ospedali Riuniti, 71122 Foggia, Italy - Tel. +39 088 1732671 - E-mail: francesco.bellanti@unifg.it

rapid increase in the serum concentrations, but also to the rapid cleavage in case of an effective empirical treatment^{6 10 11}. In patients with chronic kidney disease (CKD), PCT levels are higher than in subjects with normal renal function, and it is demonstrated that these levels are reduced after hemodialysis¹³. Thus, it is conceivable that a standard cut-off of 0.5 ng/ml could be less specific. We designed the present study to evaluate the diagnostic validity of PCT in the diagnosis of sepsis in geriatric patients presenting with CKD.

PATIENTS AND METHODS

The study was conducted at the Department of Medicina Interna Universitaria, "Ospedali Riuniti" in Foggia (Italy). We recruited 382 consecutive patients aged 65 or older. The exclusion criteria were the following: age < 65 years, active cancer, musculoskeletal trauma or recent surgery. Two groups were formed according to diagnosis of CKD (NO CKD; CKD). CKD was defined as estimated Glomerular Filtration Rate (e-GFR) less than 60 ml/min/1.73 m² at the time of admission.

Patients of both groups were divided according to the absence or the presence of sepsis (NO SEPSIS/NO CKD; SEPSIS/NO CKD; NO SEPSIS/CKD; SEPSIS/CKD). SEPSIS was defined as the presence of Systemic Inflammatory Response Syndrome (SIRS) plus suspect or proven infection with radiologic or blood culture. SIRS diagnosis was defined by the presence of two or more of the following criteria: white blood cells (WBC) > 12000/mm³ or < 4000/mm³, heart rate > 90 beats per minute, body temperature < 36°C or > 38°C, respiratory rate > 20 breaths per minute or a PaCO₂ < 32 mmHg¹⁴.

Patients included in the NO SEPSIS groups who presented with febrile episodes or leukocytosis during hospitalization were excluded.

At the hospital admission time laboratory tests such as WBC count, erythrocyte sedimentation rate (ESR), serum ferritin, C-reactive protein (CRP), uric acid and creatinine were assessed. PCT was measured by electrochemiluminescence, and the standard cut-off value was established at 0.5 ng/ml, according to the most recent literature¹⁵⁻¹⁷.

STATISTICAL ANALYSIS

Comparison between continuous variables was performed using Student's T-test or Mann Whitney's test and expressed as mean ± standard deviation of the mean (SD) or median (Interquartile Range, IR). Nominal and categorical variables were analyzed by the Chi-Square

test and expressed as *n* (%). The impact of CKD as well as sepsis presence on the circulating levels of PCT was analyzed by two-way analysis of variance (ANOVA), using CKD as row factor and sepsis as column factor. For the diagnosis of sepsis, PCT sensitivity and specificity were calculated by receiver operating characteristic curve (ROC) analysis. Statistical tests were performed using SPSS 20 software analysis. Power analysis was performed by the GPower Software.

RESULTS

We enrolled 382 consecutive patients divided in two group based on renal function: patients without CKD (NO CKD group, *n* = 188) and patients with CKD (CKD group, *n* = 194). The patients were divided according to the sepsis diagnosis: 296 (77%) without sepsis and 86 (23%) with sepsis. Baseline characteristic are summarized in Table I. There were no significant differences among septic and no septic patients as regards age, serum ferritin, as well as creatinine and e-GFR. The percentage of women was significantly higher in the non-sepsis group (*p* < 0.03). The prevalence of co-morbidities in the enrolled patients is summarized in Table II. The percentage of patients presenting with ≥ 3 co-morbidities was not different among the CKD and NO CKD groups. The most common comorbidities in both groups were hypertension, chronic obstructive pulmonary disease (COPD) and diabetes mellitus.

The mean value of WBC and ESR, as well as the median value of CRP and PCT were significantly higher in the groups with sepsis than in no septic (Tab. I). The two-way ANOVA showed that the presence of CKD (*F* = 5.072, *p* < 0.0001) or sepsis (*F* = 6.09, *p* < 0.0001), as well as the interaction between these two variables (*F* = 4.339, *p* < 0.0001) influenced serum PCT values. Post-hoc analysis demonstrated that, while there were no significant differences in circulating PCT from CKD and NO CKD groups without sepsis, septic patients with CKD presented with higher PCT levels as compared to those with NO CKD (Fig. 1).

The sensibility and specificity in the NO CKD group using normal PCT cut-off (< 0.5) were respectively 95.1% and 87.8% (AUC 0.987) (Tab. III). Very interestingly, the sensibility and specificity using normal PCT cut-off (< 0.5) were 93.3% and 30.2% respectively in the CKD group.

We performed receiver operating characteristic curve (ROC) analysis to establish PCT value with better sensitivity and specificity for the diagnosis of sepsis in the CKD group. Results showed a cut-off value of 1.7 ng/ml with sensitivity 91.1% and specificity 88.6% with Area Under the Curve (AUC) 0.932 (Fig. 2, Tab. III). The

Table I. Baseline characteristics of elderly patients without and with chronic kidney disease (CKD). Data are presented as mean \pm standard deviation, median (interquartile range) or *n* (percentage) as appropriate. Statistical differences were assessed by student's *t*-test for numerical variables and chi-square test for categorical variables.

Characteristics	NO CKD			CKD		
	NO Sepsis n. 147	Sepsis n. 41	<i>P</i> value	NO Sepsis n. 149	Sepsis n. 45	<i>P</i> value
Age, years	77.7 (\pm 7.9)	78.0 (\pm 8.2)	0.84	80.3 (\pm 7.7)	79.6 (\pm 8.4)	0.60
Sex, F	74 (50.3%)	13 (31.7%)	0.03	84 (56.4%)	20 (44.4%)	0.46
ESR, mm/h	48.8 (\pm 31.4)	77.6 (\pm 26.0)	< 0.001	56.7 (\pm 32)	69.7 (\pm 33)	0.02
CRP, mg/l	45 (7.00 to 97.50)	124 (66.0 to 187.9)	< 0.001	32.2 (7.5 to 109.8)	188 (82.6 to 260.8)	< 0.001
Ferritin, ng/ml	380.4 (\pm 42.6)	295.4 (\pm 56.2)	0.23	379.4 (\pm 81)	371 (\pm 47)	0.96
WBC, /ul	8655 (\pm 345)	14053 (\pm 6768)	< 0.001	10131 (\pm 747.9)	15521 (\pm 1031.1)	< 0.001
Creatinine, mg/dl	0.78 (\pm 0.21)	0.81 (\pm 0.19)	0.32	2.0 (\pm 1.3)	1.9 (\pm 0.8)	0.67
e-GFR, ml/min/1.73 ²	95.99 (\pm 30.3)	94.98 (\pm 26.5)	0.85	36.69 (\pm 14.2)	36.21 (\pm 11.98)	0.84
Comorbidities \geq 3 (n. patients)	64 (43.5%)	17 (41.5%)	0.81	103 (69.1%)	34 (75.6%)	0.41
PCT, ng/ml	0.07 (0.05 to 0.30)	8.5 (2.80 to 16.23)	< 0.001	0.90 (0.24 to 1.32)	21.00 (5.83 to 97.00)	< 0.001

Abbreviations: F: female; ESR: erythrocyte sedimentation rate; CRP: C protein reactive; WBC: white blood cell; PCT: procalcitonin.

Table II. Prevalence of co-morbidities of elderly patients without and with chronic kidney disease (CKD). Data are presented as *n* (percentage). Statistical differences were assessed by chi-square test.

Characteristics	NO CKD			CKD		
	NO Sepsis n. 147	Sepsis n. 41	<i>P</i> value	NO Sepsis n. 149	Sepsis n. 45	<i>P</i> value
Hypertension, <i>n</i>	86 (58.5%)	25 (61.0%)	0.86	104 (69.8%)	29 (64.4%)	0.58
Diabetes, <i>n</i>	45 (30.6%)	12 (29.3%)	0.98	75 (50.3%)	25 (55.6%)	0.61
Heart failure, <i>n</i>	29 (19.7%)	8 (19.5%)	0.99	54 (36.2%)	9 (20%)	0.05
Atrial fibrillation, <i>n</i>	31 (21.1%)	6 (14.6%)	0.50	51 (34.2%)	14 (31.1%)	0.86
Ictus, <i>n</i>	17 (11.6%)	4 (9.8%)	0.74	15 (10.1%)	6 (13.3%)	0.71
IHCD, <i>n</i>	24 (16.3%)	9 (22.0%)	0.49	43 (28.9%)	11 (24.4%)	0.70
Cirrhosis, <i>n</i>	11 (7.5%)	3 (7.3%)	0.97	11 (7.4%)	4 (8.9%)	0.82
COPD, <i>n</i>	46 (31.3%)	23 (56.1%)	0.001	58 (38.9%)	13 (28.9%)	0.29

Abbreviations: COPD, chronic obstructive pulmonary disease; IHCD, ischemic heart chronic disease.

analysis performed by Gpower software indicated 0.99 statistical power.

DISCUSSION

PCT is a validate marker to recognize bacterial sepsis in patients with symptoms and signs of infections¹⁰. PCT concentration increases in the serum within three to six hours from the development of sepsis without systemic mycoses, localized infection or SIRS. These features make the PCT a great tool for rapid differential diagnosis¹³. A systemic bacterial infection can be excluded, when the serum PCT level is < 0.5 ng/mL in SIRS patients, but it is strongly suggested if PCT

> 2.0 ng/mL; a level of \leq 2.0 ng/mL, indicates the need for re-examination after 6 to 24 hours when bacterial infection or sepsis is suspected¹⁸.

Clinical manifestations of infection or sepsis in the elderly may be atypical compared to young adults. This can make it difficult for early diagnosis especially in the elderly with co-morbidities^{8,19}. Results on the reliability of PCT to diagnose infection in aged patients are controversial. Infact, a previous study failed to demonstrate a good efficiency of PCT to detect infection in elderly people admitted to acute geriatric wards; the Authors suggested that the lack of sensitivity may be linked to the low severity of infection or to the aging process *per se*, but neither age nor comorbidity decreases the specificity of PCT²⁰. Nevertheless, the ability of PCT to




Figure 1. Serum procalcitonin (PCT) levels in all groups of studied patients. Statistical differences were assessed by two-way ANOVA and Tukey's as *post hoc* test. Abbreviations: CKD, chronic kidney disease.

Table III. Stratification of the studied population based on PCT cut off sensibility and specificity for the diagnosis of sepsis. Data are presented as *n* (percentage).

PCT Cut-off	NO CKD group		CKD group	
	NO Sepsis n. 147	Sepsis n. 41	NO Sepsis n. 149	Sepsis n. 45
< 0.5, ng/ml	87.8% (129)	4.9% (2)	30.2% (45)	6.7% (3)
≥ 0.5, ng/ml	12.2% (18)	95.1% (39)	69.8% (104)	93.3% (42)
	100% (147)	100% (41)	100% (149)	100% (45)
< 1.7, ng/ml	98.6% (145)	9.8% (4)	88.6% (132)	8.9% (4)
≥ 1.7, ng/ml	1.4% (2)	90.2% (37)	11.4% (17)	91.1% (41)
	100% (147)	100% (41)	100% (149)	100% (45)

Abbreviations: CKD, chronic kidney disease.

differentiate sepsis from localized infections or SIRS in elderly patients was demonstrated effective in another report²¹.

Chronic kidney disease (CKD) is a substantial concern in the elderly, with both an increasing incidence of treated kidney failure with dialysis as well as a high prevalence of earlier stages of CKD²². Different results are reported for the reliability of PCT in CKD. A previous study concluded that PCT is not a reliably sensitive or specific diagnostic test for bacterial infection in patients with renal impairment when using a single threshold,

although at a threshold of 0.5 ng/mL, it does have a reasonable specificity for predicting bacterial infections and a reasonable negative predictive value for predicting bacteremia²³.

Moreover, in patients with CKD a low diagnostic reliability of the current standard PCT cut-off values was shown, and a higher threshold (0.75 ng/ml) was proposed¹³. PCT levels can also increase during organ perfusion or after a severe cardiogenic shock^{24,25}.

To date, there have been poor data about the diagnostic reliability of the PCT in elderly patients with CKD.




Figure 2. Area under the receiver operating characteristic curve for procalcitonin PCT cut off in the diagnosis of sepsis (AUC 0.932).

The present study confirmed the strong correlation between WBC, ESR, CRP and PCT and inflammation, showing a significant increase in geriatric patients with sepsis. However, there are differences in elderly with CKD as compared with patients with normal renal function. Our results showed that the threshold of 0.5 ng/ml in group with sepsis and renal impairment presents a high sensibility but a poor specificity for the diagnosis of sepsis. This is consistent with previous findings about the impact of renal function on serum PCT²⁶⁻²⁷ but not in the elderly, where PCT confirms its sensibility and specificity²¹. Previous studies have shown that co-morbidities and renal impairment are associated with increased levels of cytokines, particularly IL-6, which can contribute to the inflammatory state²⁸⁻³⁰. This could be a possible mechanism linked to higher PCT values in elderly patients with CKD, since this pro-inflammatory cytokine is associated with increased levels of circulating PCT during sepsis³¹⁻³². We confirmed the significant correlation between several variables in patients with CKD with or without sepsis like WBC, PCR and PCT. We found performing the ROC curve, the value of 1.7 ng/mL as cut-off with best sensibility and specificity, respectively, of 91.1% and 88.6%.

We are aware of the limitations of our study. First, the type of study (single-center) and small sample size restricted further subgroup analysis. A second limitation is represented by the retrospective analysis. The timing between culture and serum procalcitonin was less exact than may have been ideal due to the retrospective nature of the study. Ideally, in a prospective study, these would have been simultaneous.

In conclusion, our data confirm the diagnostic reliability of PCT in the diagnosis of sepsis in geriatric patients with CKD. However, we suggest to use a threshold value of 1.7 ng/ml, which shown the best sensibility and specificity. Given the imperfect accuracy, we do not recommend that the PCT test be used in isolation; instead, we suggest that it be interpreted in the context of clinical findings.

References

- 1 Bone RC, Sibbald WJ, Sprung CL. *The ACCP-SCCM consensus conference on sepsis and organ failure*. Chest 1992;101:1481-3.
- 2 Martin GS, Mannino DM, Eaton S, et al. *The epidemiology of sepsis in the United States from 1979 through 2000*. N Engl J Med 2003;348:1546-54.

- 3 Minino AM, Xu J, Kochanek KD. *Deaths: preliminary data for 2008*. Natl Vital Stat Rep 2010;59:1-52.
- 4 Angus DC, Wax RS. *Epidemiology of sepsis: an update*. Crit Care Med 2001;29(Suppl 7):S109-16.
- 5 van Vught LA, Klein Klouwenberg PM, Spitoni C, et al. *Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis*. JAMA 2016;315:1469-79.
- 6 Singer M, Deutschman CS, Seymour CW, et al. *The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)*. JAMA 2016;315:801-10.
- 7 Vincent JL, Marshall JC, Namendys-Silva SA, et al. *Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit*. Lancet Respir Med 2014;2:380-6.
- 8 Wester AL, Dunlop O, Melby KK, et al. *Age-related differences in symptoms, diagnosis and prognosis of bacteraemia*. BMC Infect Dis 2013;13:346.
- 9 Chiesa C, Panero A, Rossi N, et al. *Reliability of procalcitonin concentrations for the diagnosis of sepsis in critically ill neonates*. Clin Infect Dis 1998;26:664-72.
- 10 Davies J. *Procalcitonin*. J Clin Pathol 2015;68:675-9.
- 11 Linscheid P, Seboek D, Schaer DJ, et al. *Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes*. Crit Care Med 2004;32:1715-21.
- 12 Hatzistilianou M. *Diagnostic and prognostic role of procalcitonin in infections*. Scientific World Journal 2010;10:1941-6.
- 13 Lee WS, Kang DW, Back JH, et al. *Cutoff value of serum procalcitonin as a diagnostic biomarker of infection in end-stage renal disease patients*. Korean J Intern Med 2015;30:198-204.
- 14 American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: *definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis*. Crit Care Med 1992;20:864-74.
- 15 Tian G, Pan SY, Ma G, et al. *Serum levels of procalcitonin as a biomarker for differentiating between sepsis and systemic inflammatory response syndrome in the neurological intensive care unit*. J Clin Neurosci 2014;21:1153-8.
- 16 Erickson YO, Samia NI, Bedell B, et al. *Elevated procalcitonin and C-reactive protein as potential biomarkers of sepsis in a subpopulation of thrombotic microangiopathy patients*. J Clin Apher 2009;24:150-4.
- 17 O'Grady NP, Barie PS, Bartlett JG, et al. *Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America*. Crit Care Med 2008;36:1330-49.
- 18 Wook KS. *Practical application of semiquantitative procalcitonin test in emergency department*. J Korean Soc Emerg Med 2008;19:665-71.
- 19 van Duin D. *Diagnostic challenges and opportunities in older adults with infectious diseases*. Clin Infect Dis 2012;54:973-8.
- 20 Stucker F, Herrmann F, Graf JD, et al. *Procalcitonin and infection in elderly patients*. J Am Geriatr Soc 2005;53:1392-5.
- 21 Gomez-Cerquera JM, Daroca-Pérez R, Baeza-Trinidad R, et al. *Validity of procalcitonin for the diagnosis of bacterial infection in elderly patients*. Enferm Infecc Microbiol Clin 2015;33:521-4.
- 22 Stevens LA, Viswanathan G, Weiner DE. *Chronic kidney disease and end-stage renal disease in the elderly population: current prevalence, future projections, and clinical significance*. Adv Chronic Kidney Dis 2010;17:293-301.
- 23 El-Sayed D, Grotts J, Golgert WA, et al. *Sensitivity and specificity of procalcitonin in predicting bacterial infections in patients with renal impairment*. Open Forum Infect Dis 2014;1:ofu068.
- 24 Boucher BA. *Procalcitonin: clinical tool or laboratory curiosity?* Crit Care Med 2000;28:1224-5.
- 25 Kuse ER, Langefeld I, Jaeger K, et al. *Procalcitonin in fever of unknown origin after liver transplantation: a variable to differentiate acute rejection from infection*. Crit Care Med 2000;28:555-9.
- 26 Castelli GP, Pognani C, Meisner M, et al. *Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction*. Crit Care 2004;8:R234-42.
- 27 Simon L, Gauvin F, Amre DK, et al. *Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis*. Clin Infect Dis 2004;39:206-17.
- 28 Landray MJ, Wheeler DC, Lip GY, et al. *Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study*. Am J Kidney Dis 2004;43:244-53.
- 29 Pecoits-Filho R, Heimbürger O, Bárány P, et al. *Associations between circulating inflammatory markers and residual renal function in CRF patients*. Am J Kidney Dis 2003;41:1212-8.
- 30 Friedman EM, Christ SL, Mroczek DK. *Inflammation partially mediates the Association of Multimorbidity and Functional Limitations in a national sample of middle-aged and older adults: The MIDUS Study*. J Aging Health 2015;27:843-63.
- 31 Nijsten MW, Olinga P, The TH, et al. *Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro*. Crit Care Med 2000;28:458-61.
- 32 Dahaba AA, Metzler H. *Procalcitonin's role in the sepsis cascade. Is procalcitonin a sepsis marker or mediator?* Minerva Anesthesiol 2009;75:447-52.